Stocks · News reference
Anteris Technologies to Present One-Year DurAVR THV Clinical Outcomes at PCR London Valves
Anteris Technologies announced that Dr. Rishi Puri of the Cleveland Clinic will present one-year clinical and hemodynamic outcomes for the DurAVR Transcatheter Heart Valve at the upcoming PCR London Valves conference.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Transcatheter Aortic Valve Replacement Market to Reach US$ 30.01 Billion by 2035 at 15.2% CAGR, Driven by Improved Clinical Outcomes and Increasing Adoption of Catheter-Based Cardiac Interventions | Exclusive Report by The Insight Partners
The global Transcatheter Aortic Valve Replacement (TAVR) market is projected to grow from US$ 8.41 billion in 2025 to US$ 30.01 billion by 2035, driven by increasing prevalence of aortic stenosis, aging populations, and rising adoption of minimally invasive cardiac procedures. Technological advancements in valve platforms and delivery systems are creating growth opportunities, with Asia Pacific emerging as the fastest-growing region.
Anteris Technologies Reports Financial Results for the Third Quarter of 2026
Anteris Technologies Global Corp. reported its financial results for the quarter ended September 30, 2026, highlighting ongoing clinical trial progress and operational updates.
8-K filing — Anteris Technologies Global Corp. (AVR)
Filed: 2026-11-12 AccNo: 0001140361-26-043093 Size: 440 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Anteris Technologies Global Corp. Files 10-Q/A Quarterly Report Amendment
Anteris Technologies Global Corp. has filed an amendment to its quarterly report (10-Q/A) with the SEC.
Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026
Anteris Technologies announced positive 30-day clinical and hemodynamic outcomes for its Medium-size DurAVR Transcatheter Heart Valve in 22 severe aortic stenosis patients. The valve demonstrated single-digit mean gradients, large effective orifice areas, no moderate or severe paravalvular leaks, and zero valve-related mortality. The company is advancing its PARADIGM pivotal trial, a randomized controlled study comparing DurAVR to commercially available TAVR devices in approximately 1,000 patients.